A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Open accessPublished version of a preprint
The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.
Abstract
A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously. Twelve pigs (n = 6/intervention) were euthanized one day post-injection, while the remaining twelve pigs were euthanized seven days post-injection (n = 6/intervention). We performed autoradiography on hippocampus and prefrontal cortex (PFC) sections with [3H]UCB-J (SV2A), [3H]MDL100907 (5-HT2AR antagonist) and [3H]Cimbi-36 (5-HT2AR agonist). One day post psilocybin injection, we observed 4.42% higher hippocampal SV2A density and lowered hippocampal and PFC 5-HT2AR density (−15.21% to −50.19%). These differences were statistically significant in the hippocampus for all radioligands and in the PFC for [3H]Cimbi-36 only. Seven days post-intervention, there was still significantly higher SV2A density in the hippocampus (+9.24%) and the PFC (+6.10%), whereas there were no longer any differences in 5-HT2AR density. Our findings suggest that psilocybin causes increased persistent synaptogenesis and an acute decrease in 5-HT2AR density, which may play a role in psilocybin’s antidepressive effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure A1 Saturation assay of [3H]UCB-J (a), [3H]MDL100907 (b) and [3H]Cimbi-36 (c) in the grey matter of the pig brain.](https://figures.cochat.ai/paper-figures/38d25f421ca64d38a1c3569974548753/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 1 Group-wise comparisons of synaptic vesicle protein 2A (SV2A) density (mean ± SD) in the hippocampus (a) and prefrontal cortex (PFC) (b) as measured with [3H]UCB-J autoradiography.](https://figures.cochat.ai/paper-figures/6f3973e6df5d483a8417e5831679ac65/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 2 Group-wise comparison of 5-HT2AR density (mean ± SD) as measured with [3H]MDL100907 and [3H]Cimbi-36 in the hippocampus (a,c) and PFC (b,d) using autoradiography.](https://figures.cochat.ai/paper-figures/aa078f12462a4e58b83778f85f9b47a1/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psilocybin has also been shown to increase the density of SV2A in vivo as measured by PET imaging (155).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“new imaging tools have the potential to identify biomarkers of psychoplastogen efficacy”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Using [3H]UCB-J in vitro autoradiography, we recently showed that a single administration of the 5-HT2A receptor agonist psilocybin was associated with higher hippocampal SV2A levels in awake pigs 24 h after administration [52].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 2×
“Calibration, quantification and data evaluation was done using ImageJ software (NIH Image, Bethesda, MD, USA) [45].”
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“We investigate brain effects one day after psilocybin administration because the days following a psychedelic experience may provide a therapeutic window to treat mood disorders [6,7].”
InfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“A follow-up seven days after a psilocybin intervention is done because this is when depressive scores have been reported to be the lowest [6].”
InfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 2×
“The increase in synaptic marker SV2A may result from the stimulation of the 5-HT2AR, TrkB and mTOR signalling pathways [10].”
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881 · cited 1×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“Both post-mortem human brain [14,15] and in vivo[16] studies in depressed individuals have shown a loss of synapses through the down-regulation of synaptic proteins and genes.”
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Cited by
Items 101–200 of 218
Ruan, Y., Yuan, R., He, J., Jiang, Y., Chu, S., & Chen, N. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01974-9 · Cited by 13
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 13
“Moreover, psilocybin resulted in increased presynaptic density in brain cortex and hippocampus of pigs (Raval et al., 2021) and upregulated expression of plasticity-related genes in rat PFC and hippocampus (Jefsen et al., 2021; Magdalena et al., 2024).”
Drewko, A. J., Habets, R. L. P., & Brunt, T. M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03169-9 · Cited by 18
“De fi nitive evidence of psychedelic-induced neuroplasticity came with direct observations of dendrito-, spino-and synapto-genesis upon the administration of LSD, DMT, DOI or psilocybin, both in vitro [32, 88] and in vivo [31, 32, 89, 90].”
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 13
“Reduced levels of both GDNF and BDNF are also found in patients with anxiety disorders [181], mood disorders [182, 183] and in SUD [169, 184].”
BackgroundInfluentialThe therapeutic potential of psychedelics
Schindler, E. A. D., & D’Souza, D. C. (2022) · Science · doi:10.1126/science.abn5486 · Cited by 13
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models
Adeyinka, D. A., Forsyth, D., Currie, S., & Faraone, N. (2025) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2025.1585367 · Cited by 12
Colosimo, F. A., Borsellino, P., Krider, R. I., Márquez, R., & Vida, T. A. (2024) · Psychoactives · doi:10.3390/psychoactives3010007 · Cited by 11
“Psilocybin also leads to lasting synaptogenesis within the hippocampal SV2A region of porcine brains up to only 7 days post intervention, which is most likely neuritogenesis but the studies looked at the level of brain tissue [71].”
BackgroundToward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity
Olson, D. E. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231054 · Cited by 13
Kramer, H. M., Hibicke, M., Middleton, J. W., Jaster, A. M., Kristensen, J. L., & Nichols, C. D. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02272-3 · Cited by 10
“This effect has been observed in rats [5, 6], mice [7 – 9], and pigs [10] following a single administration.”
Substance use and spine density: a systematic review and meta-analysis of preclinical studies
Oliva, H. N. P., Prudente, T. P., Nunes, E. J., Cosgrove, K., Radhakrishnan, R., Potenza, M. N., & Angarita, G. A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02519-3 · Cited by 11
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2026) · eLife · doi:10.7554/elife.104006.3 · Cited by 10
Vargas-Pérez, H., Grieder, T. E., & van der Kooy, D. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2033889 · Cited by 11
“In this way, the use of hallucinogenic substances decrease the production of 5-HT2A receptors (Raval et al. 2021), thus reversing the increase associated with pathological states, including depression and substance use.”
BackgroundNikolič, M., Mediano, P. A. M., Froese, T., Reydellet, D., & Páleníček, T. (2024) · medRxiv · doi:10.1101/2024.09.09.24313316 · Cited by 12
Doss, M. K., Kloft, L., Mason, N. L., Mallaroni, P., Reckweg, J. T., van Oorsouw, K. I. M., Tupper, N., Otgaar, H., & Ramaekers, J. G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241301216 · Cited by 11
“Although a single dose of psilocybin downregulates 5-HT 2A receptors in both the cortex and hippocampus (Raval et al., 2021), one possibility is that frequent ayahuasca use causes greater downregulation of inhibitory hippocampal 5-HT 2A receptors that would otherwise attenuate recollection.”
Maltby, C. J., Klein, A. K., Paschen, E., Pinto, J., Dvořák, D., Hedde, J. R., Hanks, A. N., Bianchi, M., & Hughes, Z. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251395386 · Cited by 11
“…findings support previous work showing that serotonergic psych-edelics such as LSD, DMT, and psilocybin increase dendritic spine density and synaptogenesis through 5-HT 2A receptor-dependent activation of intracellular signaling cascades (Ly et al., 2018; Raval et al., 2021; Shao et al., 2021).”
InfluentialPsychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 10
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Scholkmann, F., & Vollenweider, F. X. (2022) · Neurophotonics · doi:10.1117/1.nph.10.1.013506 · Cited by 9
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Chisamore, N., Kaczmarek, E. S., Le, G. H., Wong, S., Orsini, D. K., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00319-8 · Cited by 9
Cortical structural differences following repeated ayahuasca use hold molecular signatures
Mallaroni, P., Mason, N. L., Kloft, L., Reckweg, J. T., van Oorsouw, K. I. M., & Ramaekers, J. G. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1217079 · Cited by 9
Clarkson, R. D. O., Jabbour, M., Pelayo, D. A., Lara, D., Croix, S. L., Mumman, M., Stukas, S., Anderson, R., Meraz, D., Bangura, A., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111155 · Cited by 8
Ghaffarzadegan, R., Karimi, M., Hedayatjoo, B., Behnoud, H., Jasemi, E., Mohammadi, M., Roustaei, S., Razmi, A., & Vaseghi, S. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2428241 · Cited by 10
“A previous report has shown that pigs exposed to a hallucinogenic dose of psilocybin show an increased presynaptic density in the prefrontal cortex (Raval et al. 2021).”
Adapting psychedelic medicine for headache and chronic pain disorders
Schindler, E. A. D., & Hendricks, P. S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2246655 · Cited by 9
Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In VitroPreprint
Smedfors, G., Glotfelty, E. J., Kalani, N., Hjelle, C. P., Horntvedt, O., Wellfelt, K., Brodin, A., von Kieseritzky, F., Olson, L., & Karlsson, T. E. (2022) · Research Square · doi:10.21203/rs.3.rs-1321542/v1 · Cited by 8
ACNP 61st Annual Meeting: Poster Abstracts P1 - P270
(2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01484-1 · Cited by 9
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2026) · eLife · doi:10.7554/elife.104006 · Cited by 14
Bærentzen, S. L., Waszkiewicz, A. L., Thomsen, M., Knudsen, C., Elfving, B., & Landau, A. M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104079 · Cited by 7
“Changes in SV2A availability are proposed as a proxy of synaptic density and plasticity (Holmes, 2019; Holmes et al., 2022; Johansen et al., 2023; Finnema et al., 2016; Chen et al., 2018; Toyonaga et al., 2019; Radhakrishnan et al., 2021; Raval et al., 2021; Nabulsi et al., 2016).”
Thuery, G., Sheridan, C., Iusan, P., Brar, G., Ledden, K., Freyne, A., Kelly, J. R., & Harkin, A. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.10030 · Cited by 8
“Animal models and in vitro studies have also suggested enduring neuroplastic effects, including enhanced synaptogenesis (Ly et al ., 2018; Raval et al ., 2021; Moliner et al ., 2023; Purple et al ., 2024; Schmidt et al ., 2024; Duque et al ., 2024).”
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
Konstantinou, G., Rosenblat, J. D., Hales, S., Husain, M. I., & Blumberger, D. M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.12.005 · Cited by 7
Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy
Khan, F. A., Pandupuspitasari, N. S., Tencomnao, T., & Chuchawankul, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120882 · Cited by 8
Oommen, A. M., Roberts, K. J., Joshi, L., & Cunningham, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021200 · Cited by 8
The zebrafish for preclinical psilocybin research
Syed, O. A., Tsang, B., & Gerlai, R. T. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105381 · Cited by 9
Poulin, J. M., Bigford, G. E., Lanctôt, K. L., Giacobbe, P., Schaffer, A., Sinyor, M., Rabin, J. S., Masellis, M., Singnurkar, A., Pople, C. B., et al. (2024) · Trials · doi:10.1186/s13063-024-08268-6 · Cited by 7
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro
Salerno, J. A., & Rehen, S. K. (2024) · iScience · doi:10.1016/j.isci.2024.109631 · Cited by 7
Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability
Goldberg, J. F., Steinman, M. Q., & Stahl, S. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.101127 · Cited by 7
“…suggests that agonizing 5-HT2A with psychedelics could potentially downregulate or desensitize the receptor, which has been speculated to mediate the antidepressant effects (Pedzich et al., 2022; Raval et al., 2021; Karaki et al., 2014; de la Fuente Revenga et al., 2022; McCorvy et al., 2016).”
The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review
Palmer, C., Ferber, A. T., & Greenwald, B. D. (2025) · Brain Sciences · doi:10.3390/brainsci15060572 · Cited by 6
“An increase of 9.24% was found, indicating an increase in the number of synapses [36].”
InfluentialA single dose of cocaine raises SV2A density in hippocampus of adolescent rats
Rossi, R., Bærentzen, S. L., Thomsen, M. B., Real, C. C., Wegener, G., Grassi‐Oliveira, R., GJEDDE, A. H., & Landau, A. M. (2023) · Acta Neuropsychiatrica · doi:10.1017/neu.2023.14 · Cited by 5
Kiilerich, K. F., Lorenz, J., Scharff, M. B., Speth, N., Brandt, T. G., Czurylo, J., Xiong, M., Jessen, N. S., Casado-Sainz, A., Shalgunov, V., et al. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/gy6m9 · Cited by 5
Psychedelics and the future evolution of humanity
Winkelman, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00464 · Cited by 4
Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms
McCulloch, D. E.-W., López, J. P., Dalla, C., Ċastrén, E., Erritzøe, D., Frøkjær, V. G., Lundberg, J., Preller, K. H., Fisher, P. M., & Knudsen, G. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.103929 · Cited by 4
“Thus, if psychedelics produce synaptogenesis, one might expect an increase in the PET SV2A specific binding following administration, as was shown with UCB-J autoradiography in pigs (Raval et al., 2021).”
Self-citationStutterers’ experiences on classic psychedelics: A preliminary self-report study
Jackson, E. S., Goldway, N., Gerlach-Houck, H., & Gold, N. D. (2024) · Journal of Fluency Disorders · doi:10.1016/j.jfludis.2024.106062 · Cited by 5
Low, Z. X. B., Yong, S. J., AlRasheed, H. A., Al‐Subaie, M. F., Kaabi, N. A., Alfaresi, M. S., Albayat, H., Alotaibi, J., bshabshe, A. A. A. A., Alwashmi, A. S. S., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111279 · Cited by 4
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Song, J., Kambari, Y., Amaev, A., Ueno, F., Carmona, E. T., Luca, V. D., Pollock, B. G., Flint, A. J., Husain, M. I., Graff‐Guerrero, A., et al. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111068 · Cited by 5
Androni, X., Boyd, R. J., Rosenberg, P. B., & Mahairaki, V. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1605051 · Cited by 4
“Considering the potential of psilocybin to induce neurogenesis, synaptogenesis, and synaptic plasticity (Jefsen et al., 2020; Shao et al., 2021; Raval et al., 2021), it may represent a strong candidate for trials in human brain organoids, with the aim of exploring its potential therapeutic benefit…”
(2022) · Letters in Applied NanoBioScience · doi:10.33263/lianbs124.105 · Cited by 5
Davidson, M., Stanciu, G. D., Rabinowitz, J., Untu, I., Dobrin, R., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2480566 · Cited by 4
Cognitive control as a transdiagnostic mechanism of action in psychedelic effects
Sayalı, C., Truesdale, A., Rosen, D. S., & Barrett, F. S. (2025) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-025-01362-5 · Cited by 4
“While unexplored, this may align with initial receptor imaging work demonstrating reduced serotonin 2A receptor availability within roughly 1 day of psilocybin exposure, with a return to baseline serotonin 2A receptor availability by 1-week post-psilocybin (Raval et al., 2021).”
Molecular brain imaging of psychedelic action
Cumming, P. D., Egger, K., & Knudsen, G. M. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.02.005 · Cited by 3
Self-citationModification of natural tryptamines for the treatment of neuropsychiatric diseases
Palfreyman, M. G., Varty, G. B., Stang, E. M., Boltaev, U., Avery, K., & Nivorozhkin, A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368362 · Cited by 3
“Preclinical data demonstrated a rapid increase in spine density in mice and synaptic protein density in pigs in the prefrontal cortex after a single dose of psilocybin (Raval et al., 2021; Shao et al., 2021).”
Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney’s lesions
Iorgu, A.-M., Vasilescu, A.-N., Pfeiffer, N., Spanagel, R., Mallien, A. S., Inta, D., & Gass, P. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01699-3 · Cited by 3
A bibliometric analysis of research on psychedelics for depression treatment
Hua, H., Fu, X., Wang, W., Wang, S., Wang, D., Wu, Z., Zhang, Q., He, T., & Yang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36886 · Cited by 3
“5-HT2A 5-HT2A receptors are believed to function as antidepressants by repairing impaired synaptic plasticity in depression models [6,7].”
BackgroundVella, Y., Syrová, K., Petrušková, A., Koutrouli, I. R. A., Kútna, V., Pala, J., Nikolič, M., Šíchová, K., Mazoch, V., Jurok, R., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338232 · Cited by 3
“Our finding that psilocin promotes structural neuroplasticity is in line with other studies (Du et al., 2023; Moliner et al., 2023; Raval et al., 2021; Vargas et al., 2023).”
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2025) · eLife · doi:10.7554/elife.104006.1 · Cited by 4
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0039 · Cited by 3
“46,47 However, the fact that psilocybin leads to rapid improvements in symptoms suggests the involvement of additional mechanisms.”
Anchesi, I., Astorino, M. F., Raffaele, I., Donato, D. S., Silvestro, S., Minuti, A., Calabrò, M., Scuruchi, M., & Cipriano, G. L. (2025) · Cells · doi:10.3390/cells14231872 · Cited by 3
“Psilocybin effect on synaptic vesicle protein 2A (SV2A) suggests sustained synaptic remodeling [26].”
Managing Psychological Challenges in the Subacute (“Afterglow”) Window of Psychedelic Drug Effects
Evens, R., Uyar, A., & Majić, T. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_612 · Cited by 3
Electrophysiological effects of psilocybin co-administered with midazolam
Sutherland, M. H., Nicholas, C. R. N., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Sauder, C. J., Riedner, B. A., Smith, R. F., Hutson, P. R., Raison, C. L., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03894-x · Cited by 3
“…both structurally – via spinogenesis and dendrito-genesis – and functionally – via increased glutamatergic synaptic transmission, network activity, and functional connectivity – with effects manifesting rapidly (within hours) and persisting for days to weeks after administration [1 – 8].”
Avram, M., Menegaux, A., Müller, F., Zaczek, H., Korda, A. I., Rogg, H. V., Becker, A. M., Ley, L., Liechti, M. E., & Borgwardt, S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102791 · Cited by 2
Boehnke, K. F., Pouyan, N., & Aday, J. S. (2026) · Drugs · doi:10.1007/s40265-026-02339-5 · Cited by 2
“Preclinical studies have demonstrated that these compounds can stimulate dendritic growth [29], increase spine density [33], and enhance synaptic connectivity in cortical neurons, effects which are largely, but not exclusively [34], mediated through activation of the 5-HT2A receptor [35].”
A long trip into the universe: Psychedelics and space travel
Lerer, L. B., & Varia, J. C. (2022) · Frontiers in Space Technologies · doi:10.3389/frspt.2022.899159 · Cited by 2
McGovern, H. T., Wellman, N., Hutchinson, B. T., Oestreich, L., Cooper, S., Fonzo, G. A., & Doss, M. K. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07163-z · Cited by 2
Surówka, P., Noworyta, K., Smaga, I., Filip, M., & Ryguła, R. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1092864 · Cited by 2
“Moreover, although the 5-HT genes investigated in the present study have been choosen based on the previous reports indicating their involvement in the sensitivity to feedback, depressive disorder or antidepressant therapy (Savitz et al., 2009; Amodeo et al., 2014; Nautiyal and Hen, 2017; Phillips et al., 2018; Raval…”
BackgroundPsychodeliki - lepsza alternatywa leczenia depresji?
Gołembiowska, K. (2021) · Nauka · doi:10.24425/nauka.2021.137644 · Cited by 2
“Efekt na synaptogenez ę utrzymywa ł si ę do 7 dni, ale g ę sto ść receptora 5-HT2A powraca ł a do normy (Raval et al. 2021).”
Pathophysiology of the Serotonin System in the Nervous System and Beyond
Deurwaerdère, P. D., & Giovanni, G. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094712 · Cited by 2
Gudmundsen, F., Czurylo, J., Vo, C. T., Ruuska, J., Jessen, N. S., Baun, C., Herth, M. M., Shalgunov, V., Fisher, P. M., & Palner, M. (2024) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/mq4v2 · Cited by 2
Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol
Duan, C., Farkhondehpay, N., Safa, V., & Yuan, E. (2024) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.644 · Cited by 1
Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder
Urban, M. M., Zillich, E., Rieser, N. M., Herdener, M., Spanagel, R., Vollenweider, F. X., Preller, K. H., & Meinhardt, M. W. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03961-3 · Cited by 2
VanderZwaag, B., Robinson, J., Garcia‐Romeu, A., García-Barrera, M. A., Lake, S., & Lucas, P. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111624 · Cited by 1
Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
Chmiel, J., & Rybakowski, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052202 · Cited by 2
“These subacute synaptic gains offer a mechanistic substrate on which large-scale oscillations can reorganise [198–200].”
Psychedelic therapy and postpartum depression: priorities and prospects
Thuery, G., Crossen, F., McLoone, D., Hinds, C., Duffy, R. T., Jairaj, C., Harkin, A., & Kelly, J. R. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251408280 · Cited by 1
“However, Raval et al. 99 found that psilocybin administration in pigs was associated with significantly increased SV2A density in the hippocampus and PFC (prefrontal cortex), which was persistent at 7 days post-administration.”
Sex-dependent effects of psychedelics: review of evidence from rodent models
Marecki, R., Zaniewska, W., Hamed, A., Waszkiewicz, N., Baker, J. J., & Łukasiewicz, K. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1824073 · Cited by 1
“A recent pig study reporting psilocybin-induced increases in SV2A density and reductions in 5-HT2AR density was conducted exclusively in females (16), itself highlighting how single-sex designs, regardless of which sex is chosen, leave the question of sex-dependent translational relevance…”
Psilocybin’s effect on human brain synaptic plasticity
Johansen, A., Plavén‐Sigray, P., Madsen, M. K., Søndergaard, A., Messell, C., Geisler, M., Nasser, A., McCulloch, D. E.-W., Beliveau, V., Vassilieva, A., et al. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04285-y · Cited by 1
“The time point of one week was selected speci fi cally to investigate persistent effects, aligned with our lab ’ s previous preclinical study suggesting that this time point is associated with an increase in SV2A [25].”
Self-citationCellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
Kaup, K., Jiménez, J. H., & Aru, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106876 · Cited by 3
Gudmundsen, F., Czurylo, J., Rijsketic, D. R., Vo, C. T., Ruuska, J., Jessen, N. S., Woodruff, S., Baun, C., Herth, M. M., Shalgunov, V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75890-0 · Cited by 1
“…receptor dimerization 30 , induces neuronal spinogenesis in vitro and in vivo 32 , promotes dendritic growthinmice 33 ,alterstheexpressionofplasticity-promotinggenesin rat brain 34 , and increases density of the neuronal presynaptic marker synaptic vesicle glycoprotein 2A in rats 16 and pigs 35 .”
Levy‐Cooperman, N., Sellers, E., Glue, P., Szeto, I., Brown, D., Jarecki-Smith, J., Tyler, W. J., & McDonnell, M. B. (2026) · Pharmaceuticals · doi:10.3390/ph19091496 · Cited by 1
“…signaling without engaging the surface 5-HT2A activity associated with hallucinogenic effects at higher exposures [20] and is consistent with reported increases in presynaptic vesicle glycoprotein density in prefrontal and hippocampal regions following single-dose psilocybin in animal models [33].”
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2046-5202 · Cited by 1
Brain-wide reconfiguration of burst firing by psilocybin reveals 5-HT2A-dependent circuit dynamicsPreprint
Momi, D., Nahas, Y., Wyrick, D. G., Marks, L. C., Claar, L. D., Filippo, R. D., Seyfourian, P., Pizzagalli, D. A., Buice, M. A., Ott, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.14.744865 · Cited by 2
“…cortex (Shao et al. 2025; Shao et al. 2021), activity-dependent rewiring of cortical networks (Jiang et al. 2026), hippocampal synaptic plasticity (Hesselgrave et al. 2021; Raval et al. 2021), and shifts in functional connectivity (Daws et al. 2022) that outlast the acute effect of the drug itself.”
Self-reported effects of classic psychedelics on stutteringPreprint
Gold, N. D., Goldway, N., Gerlach-Houck, H., & Jackson, E. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.18.537312
Traitements psychédéliques et soins en addictologie
Dauré, C., & Mallet, L. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00069-x
SANTOS, R. G. D., & Hallak, J. E. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00015-x
Challenges and controversies; pharmacokinetics, linguistics, semantics and statistics
Shrewsbury, S. B., Mian, A., Houle, T. T., Donoghue, S., Schindler, E. A. D., & Dahlem, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-24705-7.00006-5
A relação entre os receptores 5-ht e os efeitos da terapia psicodélica sobre a neuroplasticidade
Souto, C. C. B., FILHO, M. A. D. C. S., Lemos, F. J. A. A. S., Silva, M. C. D. L., & Barbosa, A. P. F. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n12-153
eLife Assessment: Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
Soiza‐Reilly, M. (2025) · eLife · doi:10.7554/elife.104006.1.sa3
Lasch, A., Schweikert, T., Dora, E., Kolb, T., Schurig, H. L., & Walther, A. (2025) · Nervenheilkunde · doi:10.1055/a-2517-1621
Shah, R. J., & Sarangi, A. (2025) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2025.2500345
“…synaptogenesis, which may help counteract the neuronal atrophy associated with addiction, ultimately improving executive functioning and emotional regulation (Aleksandrova & Phillips, 2021; Knudsen, 2023; Ly et al., 2018; Olson, 2022; Perkins et al., 2021; Raval et al., 2021; Urban et al., 2023).”
Zhang, X., Liu, D.-N., Miao, Q.-S., Cai, X., Zong, L.-X., Hou, Y.-K., & Xiong, J. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174099
Microdosing Psychedelics for Cognitive Enhancement: A Naturalistic Exploration of User Experiences
Pelham, L. (2025) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/tvwc-80bg
Psilocybin in the Treatment of Mental Disorders
Sönmez, D., & Koç, A. E. (2024) · Mantar dergisi · doi:10.30708/mantar.1535344
Kleditzsch, N., Gattuso, J. J., Hannan, A. J., & Renoir, T. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70351
Changing minds: bioethical dimensions of psychedelic-assisted psychotherapy
Jacobs, E. (2025) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qq0qxrok6
Lane, C. P. (2025) · eScholarship@McGill (McGill) · doi:10.82308/37282
Psilosybiinin vaikutus neuroplastisiteettiin
Anttonen, P., & Ylönen, E. (2024) · UTUPub (University of Turku)
Chen, Q., Chen, P., Wei, T., Chamyuang, S., & Chen, B.-X. (2025) · Creative Science · doi:10.55674/cs.v18i1.264689
Husein, A., Traylor, M., Vest, M. F., Wood, B. J., Brogan, M., Thomas, A., McNeil, S. E., Bhuiyan, M. A. N., Hendricks, P. S., Kelly, J. R., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251381806
“2 7 However, psilocybin has a complex pharmacology and interacts with numerous receptors, meaning that the precise molecular mechanisms underlying its psy-chedelic and therapeutic effects are not fully established.”
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
Petrušková, A. (2026) · OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) · doi:10.25593/open-fau-2619
Inserra, A., Murray, C. J., Campanale, A., VanderZwaag, J., & Tremblay, M. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1690318 · Cited by 1
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. J. (2026) · eLife · doi:10.7554/elife.104006.2 · Cited by 1
The Effects of Psychedelic-Assisted Therapy on Illness and Death Anxiety
Amaev, A. (2024) · TSpace (University of Toronto)
Wood, B. J., Vest, M. F., Carfagno, C., Bartley, K. R., Sharma, P., Halberstadt, A. L., Blough, B. E., & Murnane, K. S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00484
Metadata
- Authors
- Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Harvard University (US)
- Corresponding author
- Hansen, Hanne Demant
- Knudsen, Gitte Moos
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 22
- Issue
- 2
- Pages
- 835
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7830000
- OpenAlex
- W3108222140
- Cited by
- 200
- References
- 48
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 40 · 2023: 41 · 2022: 33 · 2021: 17
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Horizon 2020 (813528)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psilocybin, 5-HT2A receptor, synaptic density, synaptogenesis, SV2A, hippocampus, prefrontal cortex, antidepressant mechanism, psychedelics, pig brain, receptor down-regulation
- MeSH terms
- Animals, Antidepressive Agents, Autoradiography, Brain, Female, Hallucinogens, Hippocampus, Ligands, Psilocybin, Swine, Synapses, Prefrontal Cortex, Receptor, Serotonin, 5-HT2A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.